Overall and metastasis-free survival of Afro-Caribbean patients with biochemical recurrence after radical prostatectomy.
biochemical recurrence
metastasis
prostate cancer
radical prostatectomy
salvage radiotherapy
survival
Journal
The Prostate
ISSN: 1097-0045
Titre abrégé: Prostate
Pays: United States
ID NLM: 8101368
Informations de publication
Date de publication:
12 May 2024
12 May 2024
Historique:
revised:
22
04
2024
received:
31
10
2023
accepted:
03
05
2024
medline:
12
5
2024
pubmed:
12
5
2024
entrez:
12
5
2024
Statut:
aheadofprint
Résumé
Early salvage radiotherapy is indicated for patients with biochemical recurrence after radical prostatectomy. However, for various reasons, certain patients do not benefit from this treatment (OBS) or only at a late stage (LSR). There are few studies on this subject and none on a "high-risk" population, such as patients of African descent. Our objective was to estimate the metastasis-free (MFS) and overall survival (OS) of patients who did not receive salvage radiotherapy, and to identify risk factors of disease progression. This was a single-center retrospective study that included 154 patients, 99 in the OBS group and 55 in the LSR group. All were treated by total prostatectomy for localized prostate cancer between January 2000 and December 2020 and none received early salvage radiotherapy after biochemical recurrence. Baseline characteristics were similar between groups, except for the time to biochemical recurrence. The median follow-up was 10.0 and 11.8 years for the OBS and LSR groups, respectively. The median time from surgery to LSR was 5.1 years. The two groups did not show a significant difference in MFS: 90.6% at 10 years for the OBS group and 93.3% for the LSR group. The median MFS was 19.8 and 19.6 years for the OBS and LSR groups respectively. OS for the OBS group was significantly higher than that for the LSR group (HR: 2.14 [1.07-4.29]; p = 0.03), with 10-year OS of 95.9% for the OBS group and 76.1% for the LSR group. Median OS was 16 and 15.6 years for the OBS and LSR groups, respectively. In this study, we observed satisfactory metastasis-free and OS rates relative to those reported in the scientific literature. The challenge is not to question the benefit of early salvage radiotherapy, but to improve the identification of patients at risk of progression through the development of molecular and genomic tests for more highly personalized medicine.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 The Authors. The Prostate published by Wiley Periodicals LLC.
Références
Institut national du cancer. Panorama des cancers en France ‐ édition. 2022.
Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209‐249.
Wang L, Lu B, He M, Wang Y, Wang Z, Du L. Prostate cancer incidence and mortality: global status and temporal trends in 89 countries from 2000 to 2019. Front Public Health. 2022;10:811044.
Deloumeaux J, Chatignoux E. Estimations régionales et départementales d'incidence et de mortalité par cancers en France, 2007‐2016. Santé Publique France. 2019;
Bill‐Axelson A, Holmberg L, Ruutu M, et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med. 2011;364:1708‐1717.
Han M, Partin AW, Zahurak M, Piantadosi S, Epstein JI, Walsh PC. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol. 2003;169(2):517‐523.
Nguyen CT, Reuther AM, Stephenson AJ, Klein EA, Jones JS. The specific definition of high risk prostate cancer has minimal impact on biochemical relapse‐free survival. J Urol. 2009;181(1):75‐80.
Bolla M, van Poppel H, Tombal B, et al. Postoperative radiotherapy after radical prostatectomy for high‐risk prostate cancer: long‐term results of a randomised controlled trial (EORTC trial 22911). Lancet. 2012;380(9858):2018‐2027.
Pound CR. Natural history of progression after PSA elevation following radical prostatectomy. JAMA. 1999;281:1591‐1597.
Vale CL, Fisher D, Kneebone A, et al. Adjuvant or early salvage radiotherapy for the treatment of localised and locally advanced prostate cancer: a prospectively planned systematic review and meta‐analysis of aggregate data. Lancet. 2020;396(10260):1422‐1431.
Pompe RS, Gild P, Karakiewicz PI, et al. Long‐term cancer control outcomes in patients with biochemical recurrence and the impact of time from radical prostatectomy to biochemical recurrence. Prostate. 2018;78(9):676‐681.
Tendulkar RD, Agrawal S, Gao T, et al. Contemporary update of a multi‐institutional predictive nomogram for salvage radiotherapy after radical prostatectomy. J Clin Oncol. 2016;34(30):3648‐3654.
Tilki D, Preisser F, Thamm R, et al. Salvage radiotherapy versus observation for biochemical recurrence following radical prostatectomy for prostate cancer: A matched pair analysis. Cancers. 2022;14(3):740.
Stish BJ, Pisansky TM, Harmsen WS, et al. Improved metastasis‐free and survival outcomes with early salvage radiotherapy in men with detectable prostate‐specific antigen after prostatectomy for prostate cancer. J Clin Oncol. 2016;34(32):3864‐3871.
Gervasi LA, Mata J, Easley JD, et al. Prognostic significance of lymph nodal metastases in prostate cancer. J Urol. 1989;142(2 Part 1):332‐336.
Jairath NK, Dal Pra A, Vince R, et al. A systematic review of the evidence for the decipher genomic classifier in prostate cancer. Eur Urol. 2021;79(3):374‐383.
Howard LE, Zhang J, Fishbane N, et al. Validation of a genomic classifier for prediction of metastasis and prostate cancer‐specific mortality in African‐American men following radical prostatectomy in an equal access healthcare setting. Prostate Cancer Prostatic Dis. 2020;23(3):419‐428.